Changes

In some cases, companies have "loaned" the services of their executives to advise or even lead patient groups. Ginsberg's investigation found that "the groups rarely disclose such ties when commenting or lobbying about donors' drugs. They also tend to be slower to publicize treatment problems than breakthroughs. And few openly questioned drug prices." [http://www.philly.com/mld/inquirer/14687073.htm]

Patient advocacy groups that serve as pharmaceutical fronts may display some or all of the following characteristics.